Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Astellas Signs Up Medivation Drug

by Rick Mullin
November 2, 2009 | A version of this story appeared in Volume 87, Issue 44

Astellas Pharma and Medivation have signed a deal to develop and co-commercialize MDV3100, a Medivation drug currently in Phase III trials for the treatment of prostate cancer. Under the agreement, San Francisco-based Medivation will receive an up-front cash payment of $100 million and milestone payments of up to $335 million. “We believe that MDV3100 has the unique potential to establish a new treatment approach for prostrate cancer,” Astellas CEO Masafumi Nogimori says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.